Mirae Asset Global ETFs Holdings
MNPR icon

Mirae Asset Global ETFs Holdings’s Monopar Therapeutics MNPR Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Sell
2,056
-34
-2% -$2.05K ﹤0.01% 2614
2025
Q4 		$136K Buy
2,090
+461
+28% +$37.7K ﹤0.01% 2530
2025
Q3 		$133K Sell
1,629
-593
-27% -$26.5K ﹤0.01% 2538
2025
Q2 		$79.5K Buy
+2,222
New +$80.7K ﹤0.01% 2717

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mirae Asset Global ETFs Holdings's MNPR Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Monopar Therapeutics (MNPR) stake by 1.6% in Q1 2026, selling an estimated $2.05K and leaving 2,056 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Mirae Asset Global ETFs Holdings first reported a position in MNPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $136K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 2,056 shares of Monopar Therapeutics worth $113K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings sold 34 Monopar Therapeutics shares in Q1 2026, an estimated $2.05K.
  • Monopar Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2614 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Mirae Asset Global ETFs Holdings's Monopar Therapeutics position peaked at $136K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.